Global Erlotinib Market, 2013-2023
|全球Erlotinib市場:2013年∼2023年的預測 Global Erlotinib Market, 2013-2023|
|出版日期: 2019年11月01日||內容資訊: 英文||
Erlotinib is a tyrosine kinase receptor inhibitor and classified as epidermal growth factor receptor (EGFR) inhibitor - protein-tyrosine kinase inhibitor. This is used as anticancer drug. Erlotinib is used in the therapy of advanced or metastatic pancreatic cancer, non-small cell lung cancer and any other types of cancer.
Erlotinib act as antineoplastic agents. Erlotinib therapy is associated with transient elevations in serum aminotransferase levels during therapy and rare instances of clinically apparent acute liver injury. Erlotinib added to chemotherapy improved overall survival of the patients.Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%. Peak plasma levels occur 4 hours after dosing. The solubility of erlotinib is pH dependent. Erlotinib solubility decreases as pH increases. Symptoms of overdose include diarrhea, rash, and liver transaminase elevation.
The global erlotinib market research report sheds light on the market circumstances by carrying out primary and secondary research for more than 320 hours. As per the report, the global erlotinib market is growing at a fast pace and increasing its geographical footprint rapidly. The global erlotinib market is valued at US $ xxx million dollars in 2018 which is forecast to grow at CAGR of xx% and reach a massive US $ xxx million dollars by the end of 2023 in value.
The major growth driver for Erlotinib market globally is the rapid expansion in the pharmaceutical industry. With the growing cancer disease around the world, the demand of anticancer drug increases.
Erlotinib enjoy wide usage across all major regions in the world including Europe, APAC, North America, Middle East and Africa, and Latin America. These regions serve large number of manufacturers and are hence responsible for the growth of erlotinib market globally.The companies that lead erlotinib market are Tarceva (US), Astellas Pharma & Genentech (US), Chugai & Roche (japan).
The research procedure begins with the bifurcation of various market segments of global erlotinib market, followed by detection of factors affecting the growth each segment. Then, the market forecasts were built based on the inputs given by the business leaders across erlotinib industry value chain. Market Krystal held more than 40 interviews for this study, details of which are mentioned:
By company type: Manufacturers (35%), Suppliers (25%), Consumers (20%), Researchers (10%), Independent industry consultant (10%)
By geography: North America (25%), Asia (40%), Europe (20%), Rest of the World (15%)
By designation: Top level (40%), Operation level (20%), Mid-level (40%)